156 related articles for article (PubMed ID: 29353436)
1. Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.
Purim O; Beny A; Inbar M; Shulman K; Brenner B; Dudnik E; Bokstein F; Temper M; Limon D; Matceyevsky D; Sarid D; Segal A; Semenisty V; Brenner R; Peretz T; Idelevich E; Pelles-Avraham S; Meirovitz A; Figer A; Russell K; Voss A; Dvir A; Soussan-Gutman L; Hubert A
Target Oncol; 2018 Apr; 13(2):217-226. PubMed ID: 29353436
[TBL] [Abstract][Full Text] [Related]
2. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study.
Epelbaum R; Shacham-Shmueli E; Klein B; Agbarya A; Brenner B; Brenner R; Gez E; Golan T; Hubert A; Purim O; Temper M; Tepper E; Voss A; Russell K; Dvir A; Soussan-Gutman L; Stemmer SM; Geva R
Biomed Res Int; 2015; 2015():681653. PubMed ID: 26161408
[TBL] [Abstract][Full Text] [Related]
3. Tumor profiling of gastric and esophageal carcinoma reveal different treatment options.
Miura JT; Xiu J; Thomas J; George B; Carron BR; Tsai S; Johnston FM; Turaga KK; Gamblin TC
Cancer Biol Ther; 2015; 16(5):764-9. PubMed ID: 25778705
[TBL] [Abstract][Full Text] [Related]
4. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
5. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
[TBL] [Abstract][Full Text] [Related]
6. Palliative Radiotherapy in the Presence of Well-Controlled Metastatic Disease after Initial Chemotherapy May Prolong Survival in Patients with Metastatic Esophageal and Gastric Cancer.
Hingorani M; Dixit S; Johnson M; Plested V; Alty K; Colley P; Beavis AW; Roy R; Maraveyas A
Cancer Res Treat; 2015 Oct; 47(4):706-17. PubMed ID: 25687854
[TBL] [Abstract][Full Text] [Related]
7. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer.
Prithviraj GK; Baksh K; Fulp W; Meredith K; Hoffe S; Shridhar R; Almhanna K
Dis Esophagus; 2015; 28(8):782-7. PubMed ID: 25155802
[TBL] [Abstract][Full Text] [Related]
9. Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancer.
Natori A; Chan BA; Sim HW; Ma L; Yokom DW; Chen E; Liu G; Darling G; Swallow C; Brar S; Brierley J; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Conner J; Knox J; Elimova E; Jang RW
Curr Oncol; 2018 Dec; 25(6):366-370. PubMed ID: 30607110
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.
Wainberg ZA; Soares HP; Patel R; DiCarlo B; Park DJ; Liem A; Wang HJ; Yonemoto L; Martinez D; Laux I; Brennan M; Hecht JR
Cancer Chemother Pharmacol; 2015 Jul; 76(1):61-7. PubMed ID: 25969130
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature.
Kamposioras K; Ntellas P; Nikolaou M; Germetaki T; Gazouli I; Dadouli K; Zarkavelis G; Amylidi AL; Tolia M; Mauri D
JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34926989
[TBL] [Abstract][Full Text] [Related]
13. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
[No Abstract] [Full Text] [Related]
14. A reliable risk score for stage IV esophagogastric cancer.
Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
[TBL] [Abstract][Full Text] [Related]
15. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy.
Mizrak Kaya D; Wang X; Harada K; Blum Murphy MA; Das P; Minsky BD; Estrella JS; Lin Q; Amlashi FG; Lee JH; Weston B; Bhutani MS; Matamoros A; Sagebiel T; Wu CC; Rogers JE; Thomas I; Maru DM; Skinner HD; Badgwell BD; Hofstetter WL; Ajani JA
Oncology; 2017; 93(4):243-248. PubMed ID: 28683449
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.
Kato K; Doki Y; Ura T; Hamamoto Y; Kojima T; Tsushima T; Hironaka S; Hara H; Kudo T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Kitagawa Y
Cancer Sci; 2020 May; 111(5):1676-1684. PubMed ID: 32160365
[TBL] [Abstract][Full Text] [Related]
17. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Roviello G; Petrioli R; Rosellini P; Multari AG; Conca R; Paganini G; Chiriacò G; Aieta M
Invest New Drugs; 2019 Jun; 37(3):524-530. PubMed ID: 30687871
[TBL] [Abstract][Full Text] [Related]
18. Combined modality therapy of localized gastric and esophageal cancers.
Das P; Fukami N; Ajani JA
J Natl Compr Canc Netw; 2006 Apr; 4(4):375-82. PubMed ID: 16569390
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Value of CD44 Expression in Epithelial-Mesenchymal Transition: Preliminary Data from Patients with Gastric and Esophageal Cancer.
Schizas D; Moris D; Kanavidis P; Michalinos A; Sioulas A; Pavlakis K; Machairas A; Liakakos T
In Vivo; 2016 11-12; 30(6):939-944. PubMed ID: 27815484
[TBL] [Abstract][Full Text] [Related]
20. Marital status, education, and income in relation to the risk of esophageal and gastric cancer by histological type and site.
Lagergren J; Andersson G; Talbäck M; Drefahl S; Bihagen E; Härkönen J; Feychting M; Ljung R
Cancer; 2016 Jan; 122(2):207-12. PubMed ID: 26447737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]